Actelion Ltd: PharmaVitae Profile
Datamonitor, June 2010, Pages: 76
Introduction
This analysis examines the historical and forecast performance for Actelion in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Actelion's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Actelion over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Actelion's performance against key rivals in the prescription pharmaceutical sector
- Learn how Actelion's focus on a novel pathophysiological pathway has rapidly transformed it from a startup biotech into a billion dollar company
Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–
Financial performance, 2003–
Actelion: PharmaVitae forecasts at a glance
Strategic insight
Extensive clinical development program can breathe new life into Tracleer
Novel CNS drug almorexant offers significant growth potential beyond Actelion’s existing specialist disease focus
Innovative pipeline efforts draws Big Pharma attention
SWOT analysis
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest prescription pharma product news
Q4
Q3
Q2
Q1
Latest corporate news
Q3
Q2
Q1
Future product milestones
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
CoTherix
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–
Product analysis
Product analysis, 2003–
Product analysis, 2009–
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-
Core analysis, 2009-
Expiry analysis, 2009-
Launch/core/expiry configuration, 2009–
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–
Operating costs and profit analysis
Operating costs and profit analysis, 2003–
Operating cost ratio and profit margin analysis, 2003–
Operating cost ratio and profit margin analysis, 2009–
Operating costs and profit analysis, 2009–
KEY PRODUCTS
Overview
Tracleer
Amorexant
Macitentan
Epoprostenol
Clazosentan
Zavesca
Ventavis
APPENDIX
References
Abbreviations
Exchange rates
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
